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The Pattern of HLA-DR and HLA-DQ Antigen Expression on Clonable
Subpopulations of Human Myeloid Progenitor Cells
By Rosemary L. Sparrow and Neil Williams
Three subpopulations of human myeloid progenitor cells
(CFU-GM) can be distinguished by differences in their
kinetics of development; the liquid phase pre-CFU-GM. the
day 14 CFU-.GM. and the day 7 CFU-GM. The relative cell
membrane densities of the HLA-DR and HLA-DQ antigens
expressed by the three subpopulations was investigated by
comparing the amount of antibody required to deplete
bone marrow cell preparations of each cell type. Three
separate approaches were used-complement (C’) cyto-
toxicity. antiglobulin/C’-cytotoxicity and immune rosette
depletion. Similar results were obtained for all three proce-
dures, although the latter two gave a tenfold greater
sensitivity over the standard C’-cytotoxicity method. At
saturating anti-HLA-DR antibody concentrations. 85% to
95% of cells within the three myeloid subpopulations were
found to express HLA-DR antigens. However. the relative
T HE HUMAN MAJOR histocompatibility complex
(MHC) codes for three distinct class II antigens, the
HLA-DR, DQ (DC), and DP (SB) molecules,’ which are
known to function as regulators in the immune response.
These membrane antigens have a restricted cell distribution,
being expressed predominantly by B lymphocytes, mono-
cytes, and activated T lymphocytes.2 It is therefore of interest
that hemopoietic progenitor cells of the myeloid and cry-
throid lineages also express at least one type of class II
antigen at their cell membranes.￿5 These antigens are not
found on the mature myehoid and erythroid cells, thus raising
the intriguing possibility that class II antigens may also
function as regulators of early events during hemopoiesis.
Indeed, it has been shown that activated T lymphocyte-
mediated inhibition of the more immature, clonable cry-
throid progenitors (BFU-E) is HLA-DR restricted.6 Fur-
thermore, the expression of class II antigens on myehoid
colony forming cells (CFU-GM) coincides with the ability of
prostaglandin E and acidic isoferritins to inhibit in vitro
colony formation.7’8
Human myeloid progenitor cells which form colonies of
mature progeny in cell culture can be divided into at least
three subpopulations based on differences in physical proper-
ties, response to stimuli, and kinetics of Y’ This
last characteristic is the one most commonly used to distin-
guish between these immature cell types, which are thought
to be linked in a differentiation sequence. Thus, the pre-
CFU-GM are the more immature progenitors which give rise
to the day 14 CFU-GM, which in turn generate the more
mature day 7 CFU-GM.9 The expression of HLA-DR anti-
gens on these subpopulations of CFU-GM progenitor cells
has been confirmed by several investigators, although some
discrepancies exist. A number of investigators have demon-
strated that 90% or more of the CFU-GM progenitor cell
population express HLA-DR antigens,’2’4 whereas others
have reported that only 50% are HLA-DR positive.7’8 Similar
inconsistencies have occurred for the more immature pro-
genitor cells, the pre-CFU-GM, and the mixed CFU-
GEMM colonies.8”￿’8
More recently, the pattern of HLA-DQ and DP antigen
amount of HLA-DR expressed by these subpopulations
increased from the pre-CFU-GM to the day 7 CFU-GM. The
expression of HLA-DQ antigens was considerably lower
and could only be detected by using the more sensitive
procedures. Only 50% of day 7 and 14 CFU-GM progenitor
cells expressed detectable HLA-DQ antigens. whereas a
greater proportion (80%) of the pre-CFU-GM were HLA-DQ
positive. The pattern of HLA-DQ expression on these
clonable precursors was quite distinct and opposite to the
cell membrane density of the HLA-DR antigens. Because
these three progenitor cell populations are thought to be
linked in differentiation sequence. these results provide
indirect support for the hypothesis that HIA class II anti-
gens are implicated in regulatory mechanisms during nor-
mal myeloid cell differentiation.
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expression on hemopoietic progenitor cells has been studied.
Compared with HLA-DR expression, HLA-DP molecules
are only detected on a proportion of progenitor cells,’9
whereas HLA-DQ molecules are expressed at very low
levels, ifat all.’92’
In studying the patterns of class II antigen expression on
hemopoietic progenitor cells, most reports have used antibod-
ies at saturating levels. However, by comparing the amount
of antibody required to deplete the different CFU-GM
progenitor cell populations, information concerning the rela-
tive membrane densities of the antigen can be gained. This in
turn may provide insight to the sequence of events in myehoid
cell differentiation. Using this approach with a rabbit poly-
clonal anti-class II antigen serum, Moore et al’5 found that
the pre-CFU-GM progenitor cell population expressed the
greatest abundance of class II antigen, followed by the day
14 CFU-GM, whereas the day 7 CFU-GM expressed the
least. In contrast, Broxmeyer,8 using a monoclonal antibody
(mcAb) to class II antigens, showed the reverse pattern-the
pre-CFU-GM progenitor cell population appeared not to
express class II antigens, whereas the day 7 CFU-GM
expressed the most.
In this present study, we have established the titration
curves of several anti-class II antigen mcAbs against the day
7 and 14 CFU-GM and pre-CFU-GM progenitor cells.
Thus, using two anti-HLA-DR mcAbs, the pattern of
expression reported by Broxmeyer8 was confirmed-the only
difference being that a higher proportion (85% to 95%) of
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progenitor cells from the three myeloid subpopulations
expressed HLA-DR. By using sensitive procedures, HLA-
DQ antigens were detected on a proportion of all three
subpopulations. However, the cell membrane density of the
HLA-DQ antigens was found to decline with cell matura-
tion, which is exactly the reverse of the pattern of HLA-DR
expression.
MATERIALS AND METHODS
Antisera. The B5.l and F5C9 mcAbs have been described
elsewhere.22 The B5. I mcAb is of the IgG2b subclass, and binds C’; it
recognizes a monomorphic epitope expressed on DR molecules
(personal communication, M. Steel, Co-ordinator, First Interna-
tionah Workshop on Monoclonal Antibodies to Human MHC Class
II Antigens, Edinburgh, Aug 28-Sept 2, 1983). The F5C9 mcAb is
of the IgG2a subclass, binds C’ and recognizes an epitope expressed
on DQ molecules (M. Steel, personal communication). High titred
F5C9 and B5.1 antisera obtained from hybridoma-bearing mice
were used in this present study. Another monomorphic anti-HLA
class II mcAb NEI-Ol 1 (also called 7.223) was purchased from New
England Nuclear, Boston. It is ofthe IgG2b subclass, binds C’, and is
supplied as a protein A-affinity purified solution at I mg protein per
milliliter (>95% homogeneity). McAbs used as controls were the
monomorphic anti-HLA class I antibody, 246 B824 which is of the
IgG2a subclass and binds C’; the l9A mcAb (a gift of Dr H. Zoha,
Flinders Medical Centre, Bedford Park, South Australia) which
recognizes a human common heukocyte determinant and is non-C’
fixing; and an anti-human T200 glycoprotein mcAb, F2.5.25
The sheep anti-mouse immunoghobuhin serum (SAMG) was a
generous gift of Professor I. F. C. McKenzie, Department of
Pathology, University of Melbourne. The immunoghobuhin fraction
of the antiserum was isolated by ammonium sulfate precipitation
using standard procedures.
Bone Marrow Cells. Sternal bone marrow specimens were
obtained, with informed consent, from patients undergoing thoracic/
cardiac surgery. Low-density marrow leukocytes were isolated on a
Ficoll-Paque gradient (Pharmacia, Uppsaha, Sweden), washed and
resuspended in Dulbecco’s Modified Eagles Medium (DME; Flow
Laboratories, McLean, Va) containing 5% heat-inactivated bovine
serum.
Antibody-specific Cell Depletion Procedures
All procedures used 17 x 100 mm plastic tubes (Falcon, Oxnard,
Calif).
C’-dependent cytotoxicity. Bone marrow leukocytes (1 x 10’)
in 0.4 mL were mixed with an equal volume of antibody or normal
mouse serum (NMS) at appropriate dilutions and were incubated
for 30 minutes at room temperature (RT). The cells were washed
and resuspended in 0.8 mL of a I :2 dilution of rabbit C’ (preselected
for how nonspecific toxicity; Commonwealth Serum Laboratories,
Melbourne, Australia) or heat-inactivated serum (for controls), and
incubated a further 60 minutes at 37 #{176}C. Controls included cells
incubated with: no antibody (NMS) ± C’, anti-HLA class I mcAb
246 B8 ± C’ (positive C’ control), and test antibody without C’.
Anti-globulin/C’-cytotoxicity. Bone marrow cells were treated
as above except that, following the first antibody incubation, I mg
SAMG (optimal concentration) was added. The cells were incu-
bated for ten minutes at RT and washed and resuspended in rabbit
C’ as described. The non-C’ binding 19A mcAb was included as a
control to assess the effectiveness of second antibody binding.
Immune rosette depletion. Bone marrow cells ( 1 x I 06) were
incubated with antibody as above, washed three times, and resus-
pended in 0.5 mL of DME/5% serum. Controls included cells
incubated with NMS or 246 B8 mcAb. Rosette formation was
performed as described elsewhere.￿’ Briefly, SAMG was coupled to
sheep erythrocytes by chromic chloride, and 0.1 mL of a 2%
erythrocyte suspension was added to the bone marrow cells. After a
gentle centrifugation at 75 g for three minutes, the cell mixture was
incubated for 30 minutes at RT to allow rosette formation. The cell
pellet was then carefully resuspended in its supernatant and 0.4 mL
of Ficohl-Paque was underlaid. Following centrifugation at 200 g for
five minutes, the nonrosetted (interface) cells were collected.
For all procedures, the cells were given a final wash and divided
for subsequent CFU-GM assays.
Myeloid Progenitor Cell Colony Assays
A 50% nonspecific loss of cells during the antibody-cell depletion
procedures was assumed. Hahfthe cells (-.2.5 x i0￿ total for control
tubes) from each tube were assayed for pre-CFU-GM, while the
remaining half were equally divided into six cultures (-4 x i0￿
cells/culture) for day 7 and 14 CFU-GM.
Day 7 and 14 CFU-GM. For soft agar culture, DME containing
the following supplements was used as the plating medium: 2mmoh/
L ofglutamine, I mmol/L ofsodium pyruvate, 0.8% 50 x minimum
essential amino acid mixture, 0.6% 100 x nonessential amino acid
mixture, 16 Mg/mL L-asparagine, 8 jsg/mL L-serine, 0.6% vitamin
mixture, 100 IU/mL penicillin, 100 jzg/mL streptomycin, 0.12%
sodium bicarbonate (all from Flow), l0￿ mol/L of 2-mercaptoetha-
noh, I 5% fetal calf serum (FCS, Commonwealth Serum Laborato-
ries) and 0.3% bactoagar (Difco, Detroit). The cells were diluted in
6.5 mL of plating medium, containing an optimal concentration of
colony-stimulating activity (CSA), and then equally divided into six
35-mm plastic culture dishes (Kayhine, Adelaide, South Australia).
The cultures were incubated at 37 #{176}C in a humidified 10% CO2
atmosphere; three plates were scored for colonies (> 50 cells) after
seven days, and the remaining three were scored after 14 days of
incubation.
Pre-CFU-GM. Pre-CFU-GM progenitor cells can be defined by
their ability to give rise to CFU-GM following incubation in liquid
suspension culture.27 In I 7 x 100 mm Falcon 2057 tubes, cells
(-2.5 x 10￿) were suspended in I mL of DME containing 15% FCS,
l0￿ moh/L of 2-mercaptoethanol and 10% CSA. After five days of
suspension culture (maximal CFU-GM expansion was found to
occur after four to five days of liquid culture and then to decline), 0.3
mL of cells was taken and plated in triplicate CFU-GM soft-agar
cultures containing CSA, as described above. The plates were
incubated for a further seven days, and CFU-GM colonies were
scored. Under these conditions, expansion of the CFU-GM numbers
ranged from 160% to 224% (mean 182%) as compared with day 7
CFU-GM numbers obtained without prior liquid culture.
Sources of CSA. Conditioned medium (CM) from the human
fibroblast cell line 56372829 was routinely used as a source of CSA.
For the preparation of 5637-CM, cells were grown in DME/5%
bovine serum containing Cytodex-3 beads (Pharmacia, Uppsala,
Sweden). After five days of culture, the CM was pooled, concen-
trated fivefold, and dialyzed against 5 vol of deionized-distilled
water using an Amicon TCF Thin Channel System with a YMIO
filter (Amicon, Lexington, Mass). Following sterilization through a
0.2-am filter, the 5637-CM was stored at -20 #{176}C where it retained
biological activity for at least six months. The optimum concentra-
tion of various batches of 5637-CM was found to be 5% to 10% for
cultures containing 5 x l0￿ cells per milliliter (day 7 CFU-GM
numbers, 52 ± 15, mean + SEM, n ￿ 40). For some experiments, as
indicated, CM from the human macrophage cell line GCT￿#{176} (GIB-
CO, Grand Island, NY) was used at a 10% final concentration.
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RESULTS
Pattern of expression of the HLA-DR antigens. Figure
I A shows the results of a representative experiment (one of
four separate experiments) in which the anti-HLA-DR
mcAb B5.1 was titrated for inhibition of CFU-GM colony
formation in the C’-dependent cytotoxicity assay. At high
concentrations of mcAb (1 :100 dilution), colony formation
for the three CFU-GM progenitor cell compartments (day 7
and 14 CFU-GM and pre-CFU-GM) was inhibited by 85%
to 95%, thus confirming the results ofothers.’2’4 However, at
lower concentrations of mcAb, the sensitivities of the CFU-
GM compartments diverged, with the day 7 CFU-GM
progenitor cells being the most sensitive to anti-HLA-DR/C’
treatment, followed by the day 14 CFU-GM, whereas the
pre-CFU-GM progenitor cells were the least sensitive. This
was evidenced by the 50% titration points which show, in Fig
IA for example, that the day 7 CFU-GM titrated at a
B5.1-antibody dilution of 2 x iO￿, the day 14 CFU-GM at
iO-￿, whereas the pre-CFU-GM had the lowest titer at 0.3 x
iO-￿. Thus, a tenfold increase (range 5 to 15) in the
expression of HLA-DR antigens was demonstrated for the
day 7 CFU-GM as compared with the pre-CFU-GM. This
pattern of HLA-DR expression is similar to that described
by Broxmeyer,8 the only difference being in the proportion of
progenitor cells expressing detectable HLA-DR antigens at
saturating antibody levels.
0 ! ￿ ￿ ￿1
Fig 1 . Effect of pretreatment with anti-HLA-DR mcAb (B5.1)
on colony formation of the three myeloid progenitor cell subpopu-
lations using XC’-cytotoxicity (A). antiglobulin/C’-cytotoxicity (B),
or immune rosette depletion (C). Experiments were done sep.-
rately using different sources of bone marrow. Results are the
mean ± SE of triplicate cultures. Percentage of inhibition is
relative to NMS or C’ controls appropriate to the assay used.
￿ PRE CFU-GM; O-O, Day 7; -. Day 14.
To ensure that this pattern of HLA-DR antigen expression
was not attributed to the C’ binding characteristics of the
C’-cytotoxicity method used, the titration curves were estab-
lished using two different procedures-anti-globulin/C’-
cytotoxicity and immune rosette depletion. The representa-
tive experiments shown in Figs 1B and C indicate that the
same pattern of HLA-DR antigen expression was obtained
regardless ofthe procedure used. Identical results were found
using a second anti-class II antigen mcAb, NEI-Ol 1 (data
not shown).
To compare the sensitivities of the three procedures, B5. 1
titration curves for the day 7 CFU-GM progenitors were set
up using the same source of bone marrow. The results showed
that both the antiglobulin/C’cytotoxicity and immune
rosette depletion procedures have a tenfold greater sensitivity
than the standard C’-cytotoxicity method (Table 1). This is
in agreement with previous findings.263’
Effect of a different source of CSA. Subclasses of
human CSAs have been described which appear to influence
different biological properties of CFU-GM.9”#{176} For these
present experiments, 5637-CM was routinely used as a
source of CSA. Morphological analysis of the colony types
supported by 5637-CM has not indicated any marked differ-
ence compared to other CSAs (Sparrow and Williams,
unpublished observations). However, since previous reports
investigating the expression ofclass II antigens on CFU-GM
progenitor cells have not used 5637-CM, the titration curves
were repeated using GCT-CM as an alternative source of
CSA. The same pattern of HLA-DR expression, using the
NEI-Ol 1 mcAb, was obtained for both GCT-CM and 5637-
CM (Fig 2), indicating that the results are not attributed to a
unique activity in 5637-CM.
Pattern ofexpression ofthe HLA-DQ antigens. Experi-
ments similar to those described above were set up using the
anti-HLA-DQ mcAb, F5C9.22 This antibody has previously
been found to have strong activity against normal peripheral
blood B lymphocytes in the C’-dependent cytotoxicity. Initial
experiments using this same procedure indicated very little
(0% to 10%) myeloid colony inhibitory activity, even at high
concentrations (1 :100 dilution) of the F5C9 mcAb. These
results are in agreement with those ofothers, suggesting that
the HLA-DQ antigens are weakly expressed by the CFU-
GM progenitors.’￿2’
However, a different set of results was obtained when the
more sensitive methods, the antiglobulin/C’-cytotoxicity or
Table 1 . Comparison of Sensitivities of Three Assay Procedures
Used to Determine Expression of HLA-DR Antigens on Day 7
CFU-GM Progenitor Cells
Inhibition (%) of CFU-GM after Treatment by
B5. 1 mcAb Antiglobulin/ Rosette
Dilution C’-cytotoxicity C’-cytotoxicity Depletion
1:102 95±1 97±2 94±1
i:iO￿ 83±2 95±2 96±2
1:10’ 63±6 73±3 85±3
i:iO￿ 24±5 59±2 61±3
1:106 8±4 28±4 33±4
Results are the mean ± SE of triplicate cultures.
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Fig 2. Comparison of colony-stimulating activities from GCT-
CM (A) and 5637-CM (B) on bone marrow cells pretreated with
anti-HLA-DR mcAb (NEI-Ol 1) and C’. Experiments were done
separately using different sources of bone marrow. Results are the
mean ± SE of triplicate cultures. Percentage of inhibition is
relative to C’ controls. O-O, Day 7; -. Day 14.
immune rosette depletion, were used. At high concentrations
of F5C9 mcAb, -50% (range 42% to 72%) of day 7 and 14
CFU-GM were found to express HLA-DQ antigens, whereas
an even greater proportion (75% to 85%) of the pre-CFU-
GM were HLA-DQ antigen positive (Fig 3). Information
from the antibody titration curves suggests that the level of
HLA-DQ antigen expression decreases with increasing
maturation such that the pre-CFU-GM progenitor cells
express the greatest level, followed by the day 14 CFU-GM,
whereas the day 7 CFU-GM progenitors express the least.
Comparison of the 40% titration points, for example, mdi-
cates a 50-fold (range 25 to 200) decrease in HLA-DQ
antigen expression by the day 7 CFU-GM relative to the
￿00
80
￿ 80
￿ 40
A
￿,oo B
“80
￿ o.-------±--
￿ 80
J::
0
,0_, i￿￿’ ￿0￿’ ￿0-’ ￿0-’ ￿0-’
FINAL DILUTION OF ANTI-DO LOG SCALE)
Fig 3. Effect of pretreatment with anti-HLA-DQ mcAb (F5C9)
on colony formation of the myeloid progenitor cell subpopulations
using antiglobulin/C’-cytotoxicity (A) or immune rosette depletion
(B). Different sources of bone marrow were used for each experi-
ment. Results are the mean ± SE of triplicate cultures. Percentage
of inhibition is relative to the appropriate NMS or C’ controls.
￿-& PRE CFU-GM; O-O. Day 7; -. Day 14.
pre-CFU-GM progenitors. This pattern of expression is the
reverse of that found for the HLA-DR antigens.
Patterns ofexpression ofnon-HLA class II antigens. To
show that technical manipulations were not accountable for
the patterns of HLA-DR and DQ antigen expression pre-
sented here, titration curves were established using two
mcAbs which recognize different and unrelated cell mem-
brane antigens. The 246 B8 mcAb recognizes a monomor-
phic epitope on HLA class I antigens, whereas the F2.5
mcAb recognizes the human homologue of the murine T200
glycoprotein (or leukocyte-common antigen). For both anti-
bodies, no significant difference was observed between the
titration curves for day 7 and day 14 CFU-GM progenitor
cells (Fig 4). Thus, unlike the HLA-DR and DQ molecules,
the expression of the HLA class I and T200 antigens is static
during this period of myeloid cell differentiation.
DISCUSSION
In this study, the cell membrane density of the HLA-DR
antigens was shown to increase with myeloid progenitor cell
maturation. An average tenfold increase in the expression of
HLA-DR antigens by day 7 CFU-GM progenitor cells as
compared with the pre-CFU-GM was demonstrated. These
results confirm those of Broxmeyer,8 although they vary with
respect to the observed maximum levels of HLA-DR antigen
expression. Broxmeyer found, even at high anti-HLA-DR
mcAb concentrations, that only 50% of the day 7 and 14
CFU-GM progenitors expressed the antigen, whereas the
pre-CFU-GM appeared not to express HLA-DR at all.8 Our
results show that 85% to 95% of cells from the three myeloid
progenitor cell compartments studied express HLA-DR anti-
gens. Presumably the variance in results between those
reported here and those reported by Broxmeyer can be
attributed to the different sources of complement used, an
effect recently illustrated by Falkenburg et al,32 who showed
100
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Fig 4. Comparison of inhibition of day 7 and 14 CFU-GM
colony formation following pretreatment with: (A) anti-HIA class I
mcAb, 246 B8 and C’-cytotoxicity; or (B) anti-T200 glycoprotein
mcAb, F2.5 and antiglobulin/C’-cytotoxicity. Results are the
mean ± SE of triplicate cultures. Percentage of inhibition is
relative to the appropriate C’ controls. O-O. Day 7; -. Day
14.
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that hemopoietic progenitor cells differ in their sensitivities
to complement. However, the use of complement-dependent
procedures in this report does not seem to have biased the
results in any way, because similar results were obtained
using a noncomplement procedure, immune rosette deple-
tion.
The demonstrable increase in the level of HLA-DR anti-
gen expression during CFU-GM progenitor cell maturation
supports the hypothesis that these antigens have a biological
function in hemopoiesis. The exact nature of such a role
remains unknown. An association between HLA-DR expres-
sion and modulation of myeloid differentiation by prosta-
glandin E and acidic isoferritins has been suggested.8”7
However, in contrast to our data and those of other investiga-
tors,’2’4”9’2’ these authors found that only 50% of the CFU-
GM progenitor cells expressed HLA-DR; thus, the correla-
tions observed must remain uncertain.
It could be argued that the observed increase in H LA-DR
expression may not be unique but could be a common
occurrence for cell membrane proteins expressed by the
CFU-GM progenitor cells. Evidence against this, however, is
that the expression of the separately regulated HLA class I
and T200 glycoproteins remains constant during the three
stages of myeloid cell differentiation studied. Furthermore,
the expression of the HLA-DQ antigens was found to decline
with cell maturation.
Of particular interest in this study was the demonstrated
pattern of HLA-DQ antigen expression by myeloid progeni-
tor cells. At saturating antibody levels, -50% of the day 7
and 14 CFU-GM progenitor cells expressed detectable
HLA-DQ antigens, whereas an even greater proportion
(80%) of pre-CFU-GM progenitors were HLA-DQ positive.
Comparison of the titration curves for the three cell popula-
tions indicated that the pre-CFU-GM expressed 50 times
more HLA-DQ (range 25 to 200) than did the day 7
CFU-GM. This pattern of expression is the reverse to that
found for the HLA-DR antigens (see Fig 5 for a diagram-
matic representation).
These results could only be obtained when very sensitive
procedures were used. The anti-HLA-DQ mcAb F5C9 used
in this study is strongly active in the C’-cytotoxicity assay
when B lymphocytes are used as target cells.33 The fact that
very little F5C9-binding could be detected on myeloid pro-
genitor cells using the C’-cytotoxicity method suggests that
the cell membrane density of the HLA-DQ antigens is
comparatively low or that the antibody affinity is lower for
myeloid HLA-DQ antigens than for B lymphocyte antigens.
This may explain the results of other investigators who were
unable to demonstrate HLA-DQ antigen expression by
CFU-GM.’￿2’ Falkenburg et al2’ used a conventional anti-
CELL MATURATION
PRE DAY14 DAY7
CFU-GM ￿ CFU-GM ￿ CFU-GM
HLA-DR
HLA-OO
I.$LACLASS1 ￿ ￿ 1
Fig 5. Diagrammatic representation of the changes in cell
membrane densities of the HLA-DR and DO antigens expressed
during myeloid cell maturation from the pre-CFU-GM to the more
mature day 7 CFU-GM. The expression of other cell surface
antigens, such as the HLA class I and T200 glycoproteins remains
constant (broken lines represent extrapolated results).
DQw1 alloantisera with the C’-cytotoxicity procedure.
FACS has also been used.’9’2#{176} However, this procedure is
limited by the fact that the bone marrow myeloid cells
display high nonspecific staining. To overcome this problem,
the threshold for positive sorting was raised, reducing the
overall sensitivity of the procedure.2#{176} Linch et al’9 used
immune rosette depletion, but their definition of a day 7
CFU-GM colony varied considerably from ours, and thus the
results are not directly comparable.
We are currently pursuing the investigation of HLA-DQ
antigens on hemopoietic cells. It is possible that the apparent
decrease in HLA-DQ antigen expression may result from
increased glycosylation of the molecule such that the F5C9
mcAb can no longer recognize its reactive determinant. No
data is available to suggest that this is the case. The biologic
function of the HLA-DQ antigens on myeloid progenitor
cells is unknown. However, in the immune system, HLA-DQ
antigens predominantly modulate functions involving the
production of suppressor and/or cytotoxic T lymphocytes,
whereas the HLA-DR antigens are directly implicated in
helper T lymphocyte function.M It is therefore tempting to
speculate that if similar roles are played by these antigens in
hemopoiesis, the decrease in HLA-DQ and corresponding
increase in HLA-DR expression seen during myeloid proge-
nitor cell maturation reflect changes in regulatory mecha-
nisms.
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